Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial
John R Guyton, Sergio Fazio, Adeniyi J Adewale, Erin Jensen, Joanne E Tomassini, Arvind Shah, Andrew M Tershakovec, John R Guyton, Sergio Fazio, Adeniyi J Adewale, Erin Jensen, Joanne E Tomassini, Arvind Shah, Andrew M Tershakovec
Abstract
Objective: To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients.
Research design and methods: This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks.
Results: FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5% taking E/S+N versus 2.6% taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4% taking E/S+N versus 0.4% taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patients with baseline diabetes, 13.9% taking E/S+N and 11.6% taking E/S underwent antidiabetic treatment modification.
Conclusions: Increased FG and new-onset diabetes with E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.
Trial registration: ClinicalTrials.gov NCT00271817.
Figures
References
- Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415–420
- American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl. 1):S62–S69
- Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564–1572
- Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol 2010;105:487–494
- Ford ES, Li CY, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31:1898–1904
- Nathan DM, Davidson MB, DeFronzo RA, et al. ; American Diabetes Association Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753–759
- Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342–347
- Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723–726
- Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381
- Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263–1270
- Grundy SM, Vega GL, McGovern ME, et al. ; Diabetes Multicenter Research Group Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568–1576
- Vega GL, Cater NB, Meguro S, Grundy SM. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005;95:1309–1313
- Rasouli N, Hale T, Kahn SE, Spencer HJ, Elbein SC. Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals. J Clin Endocrinol Metab 2005;90:5825–5833
- Walters RW, Shukla AK, Kovacs JJ, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009;119:1312–1321
- Lai E, Waters MG, Tata JR, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol 2008;2:375–383
Source: PubMed